September 15, 1994Annals of Internal Medicine

Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin

View Full Paper

Ask AI

Bookmark

Why the study?

Does continuous intravenous prostacyclin improve exercise capacity, hemodynamics, and survival in patients with primary pulmonary hypertension?

Structured PICO

Does continuous intravenous prostacyclin improve exercise capacity, hemodynamics, and survival in patients with primary pulmonary hypertension?

Population

18 patients with primary pulmonary hypertension (1 NYHA class II, 13 NYHA class III, and 4 NYHA class IV).

Intervention

Continuous intravenous prostacyclin administered by portable infusion pumps, added to background anticoagulant therapy.

Comparator

Historical controls who received standard therapy from the National Institutes of Health Primary Pulmonary Hypertension Registry (n=31) for the survival analysis.

Outcome

Exercise capacity (6-minute walk distance), hemodynamics (cardiac index, mean pulmonary artery pressure, total pulmonary resistance), and survival.

Continuous intravenous prostacyclin provides sustained clinical and hemodynamic improvements and significantly improves long-term survival in patients with severe primary pulmonary hypertension.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support survival benefit of prostacyclin in primary pulmonary hypertension; leaves open confirmation in randomized trials.

Cite This Study

Robyn J. Barst (1994) studied this question.

synapsesocial.com/papers/6a7cc2d58a7077a9e43f76bb https://doi.org/10.7326/0003-4819-121-6-199409150-00003

View Full Paper

Ask AI

Bookmark

Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin

Structured PICO

Discussion

Implication

Cite This Study

Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider